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MaOBJECTIVES A Bayesian network meta-analysis was performed comparing the efﬁcacy and safety of drug-eluting bal-
loons (DEB), drug-eluting stents (DES), or plain old balloon angioplasty (POBA) for treatment of in-stent restenosis (ISR).
BACKGROUND Optimal treatment options for ISR have not been well established.
METHODS Randomized, controlled trials comparing DEB, DES, and POBA for the treatment of ISR after percutaneous
coronary intervention with bare metal stent or DES were included. The primary outcome was target lesion revasculari-
zation (TLR). The pairwise posterior median odds ratio (OR) with 95% credible interval (CrI) was the effect measure.
RESULTS This analysis included 2,059 patients from 11 RCTs. The risk of TLR was markedly lower in patients treated with
DEB (OR: 0.22, 95%CrI: 0.10 to0.42) or DES (OR: 0.24, 95%CrI: 0.11 to 0.47) than in those treatedwith POBA in a random-
effects model. In a comparison of DEB and DES, the risk of TLR (OR: 0.92, 95% CrI: 0.43 to 1.90) was similar. The risk of MI
or all-causemortality was lowest in the DEB group compared with the DES and POBA groups, which did not meet statistical
signiﬁcance. The risk of major adverse cardiac events, which was mainly driven by TLR, was also signiﬁcantly lower in the
DEB or andDES group (OR: 0.28, 95%CrI: 0.14 to0.53) than in the POBA group, but it was similar between theDEB andDES
groups (OR: 0.84, 95% CrI: 0.45 to 1.50). The probability of being ranked as the best treatment was 59.9% (DEB), 40.1%
(DES), and 0.1% (POBA) in terms of TLR, whereas it was 63.0% (DEB), 35.3% (POBA), and 1.7% (DES) in terms of MI.
CONCLUSIONS Local drug delivery by DEB or DES for ISR lesions was markedly better than POBA in preventing TLR,
but not for MI or mortality. Among the 2 different strategies of drug delivery for ISR lesions, treatment with DEB showed
a trend of less development of MI than did treatment with DES. (J Am Coll Cardiol Intv 2015;8:382–94) © 2015 by the
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383ABBR EV I A T I ON S
AND ACRONYMS
ACCF/AHA/SCAI = American
College of Cardiology/American
Heart Association/Society for
Cardiovascular Intervention
BMS = bare metal stent(s)
DAPT = dual-antiplatelet
therapy
DEB = drug-eluting balloon(s)
DES = drug-eluting stent(s)
%DS = percentage of
diameter stenosis
ISR = in-stent restenosisI n-stent restenosis (ISR) has been a major draw-back with percutaneous coronary intervention(PCI). Intervention of ISR lesions constituted
20% to 40% of all PCIs in the era of bare metal stents
(BMS) (1). Although drug-eluting stents (DES) substan-
tially reduced the rates of ISR compared with BMS, the
expansion of indications for PCI to complex coronary
lesions in high-risk patients still makes ISR an impor-
tant issue with a incidence of 3% to 20% of patients
(1,2). Given its progressive onset, ISR has been
believed to be a benign phenomenon. However, a sub-
stantial proportion of ISR after BMS or DES implanta-
tion can present as unstable angina (26% to 53%
for BMS, 16% to 66% for DES) or even as myocardialSEE PAGE 395
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
PCI = percutaneous coronary
interventions
POBA = plain old balloon
angioplasty
RCT = randomized,
controlled trial
TLR = target lesion
revascularization
TVR = target vessel
cularizationinfarction (MI) (3.5% to 20% for BMS, 1% to 20% for
DES), leading to a worse clinical outcome than in those
without ISR (1,2). Despite the clinical and prognostic
importance of ISR, current evidence regarding treat-
ment options for ISR have been limited (1). American
College of Cardiology/American Heart Association/
Society for Cardiovascular Intervention (ACCF/AHA/
SCAI) guidelines for PCI recommend BMS ISR to be
treated by DES (Class I, Level of Evidence: A) and DES
ISR by plain old balloon angioplasty (POBA), BMS, or
DES (3). The European Society of Cardiology/European
Association for Cardio-Thoracic Surgery guidelines for
myocardial revascularization recommend a drug-
eluting balloon (DEB) to treat BMS ISR (Class IIa, Level
of Evidence: B) (4). However, the ACCF/AHA/SCAI
guidelines are on the basis of limited trials and 1
meta-analysis, especially with regard to the treatment
strategy for DES ISR. In addition, the European Society
of Cardiology/European Association for Cardio-
Thoracic Surgery guidelines for treating BMS ISR
were also on the basis of 1 ﬁrst-in-human trial and 2
randomized, controlled trials (RCTs) with a relatively
small sample size (5–7). Currently, there is no clear
optimal treatment option for ISR for either BMS ISR
or DES ISR. Although DEB coated with paclitaxel is an
emerging treatment option for ISR without implanta-
tion of additional metal alloy, RCTs on the use of DEB
have been sporadically conducted and have focused
on angiographic outcomes with limited statistical po-
wer for clinical outcomes. Therefore, we performed
comprehensive Bayesian network meta-analysis of
RCTs to compare the efﬁcacy and safety of the current
treatment options (DEB, DES, and POBA) for ISR.
METHODS
An expanded description of the study methods are
presented in the Online Appendix.DATA SOURCES AND SEARCHES. PubMed,
Embase, Cochrane Central Register of
Controlled Trials, and the U.S. National In-
stitutes of Health registry of clinical trials,
and relevant websites were all searched for
pertinent published or unpublished studies.
The detailed search strategy is presented in
the Online Appendix.
STUDY SELECTION. We included RCTs
assessing treatment strategies for BMS and
DES ISR that met the following criteria. First,
we included only RCTs. Second, each trial
compared various types of intervention for
BMS or DES ISR (e.g., DEB vs. DES, DEB vs.
POBA, DES vs. POBA, or DEB vs. DES vs.
POBA). Finally, clinical outcomes of efﬁcacy
(target lesion revascularization [TLR] or
target vessel revascularization [TVR]) and
safety (MI or all-cause mortality) during the
minimal follow-up period of 6 months were
clearly reported. We did not include trials
that used cutting balloon angioplasty,
vascular brachytherapy, or rotablation for ISR
treatment.
DATA EXTRACTION AND QUALITY ASSESSMENT.Summary data as reported in the published articles
were used in the analysis. A standardized form was
used to extract detailed information from the RCTs.
We primarily focused our analysis on the effect of the
treatment strategies on TLR, not on the angiographic
surrogate markers of restenosis (e.g., late lumen loss).
The quality of eligible RCTs was assessed using the
Cochrane Collaboration’s tool for assessing the risk of
bias for RCTs (Online Table 1). The last search was
performed in March 2014.
OUTCOMES AND DEFINITIONS. The primary out-
come was the incidence of TLR after treatment of ISR
at the longest available follow-up. If the included
trials reported only TVR instead of TLR, it was used
for the primary outcome analysis. Secondary clinical
outcomes included the incidence of any MI, all-cause
mortality, and major adverse cardiovascular events
(MACE) at the longest available follow-up. The deﬁ-
nitions of repeat revascularization and MI in the each
included trials are presented in Online Table 2. Sec-
ondary angiographic outcome included the rate of
binary restenosis (>50% of diameter stenosis) at 6- to
9-month follow-up angiography.
DATA SYNTHESIS AND ANALYSIS. A Bayesian ran-
dom effects model for multiple treatment com-
parisons was constructed to compare primary and
secondary outcomes among the 3 treatment groups
revas
FIGURE 1 Flow Dia
(A) The study ﬂow d
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384(DEB, DES, and POBA). Odds ratios (ORs) with 95%
credible intervals (CrIs) are presented as summary
statistics. Sensitivity analyses were performed by:
1) repeating the main computations using a ﬁxed-
effects model; 2) analysis was restricted to trials
with BMS ISR and, DES ISR; 3) ﬁrst-generation DES as a
treatment option for the ISR; 4) dual-antiplatelet agent
treatment (DAPT) duration longer than 6 months,
5) DAPT duration <6 months, or 6) blinded outcome
assessment by an independent clinical event adjudi-
cation committee. The present study was performed
in compliance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines; the review protocol has not been regis-
tered (Online Table 3).
RESULTS
An expanded description of the study methods (trial
characteristics, risk of bias within trials) are pre-
sented in the Online Appendix.
SEARCH RESULTS. We identiﬁed 1,140 citations,
retrieved 27 studies for detailed evaluation, and
found 11 RCTs that met the inclusion criteria
(Figure 1A) (7–17) after excluding 16 studies whose
characteristics are summarized in the Online
Appendix. The interobserver agreement for studygram of Trial Selection and Network Plot of Meta-Analysis Model
iagram depicted following the PRISMA guidelines. (B) Network plot of meta-a
osis; POBA ¼ plain old balloon angioplasty.selection was high (l ¼ 0.91). The 11 RCTs included a
total of 2,059 patients with BMS or DES ISR. They
were treated with DES (n ¼ 808, 39.2%), DEB (n ¼ 694,
33.7%), or POBA (n ¼ 557, 27.1%). Among 11 RCTs,
3 trials compared DES with DEB, 4 trials compared
DEB with POBA, 3 trials compared DES with POBA,
and one 3-arm trial compared DES, DEB, and POBA.
The primary outcome (TLR) was collected from the
longest available follow-up data, whereas 1-year
secondary clinical outcomes (TLR, MI, all-cause
mortality, and MACE) were extracted from the
earlier reports. Among the 11 RCTs, 2 trials reported
short- and long-term data separately: 1) the RIBS II
(Restenosis In-Stent: Balloon Angioplasty vs. Elective
Sirolimus-Eluting Stenting) trial separately reported
1-year (2006) and more than 3-year follow-up data
(2008) (9,18); and 2) the PACCOCATH ISR (Treatment
of In-Stent Restenosis by Paclitaxel-Coated Balloon)
trial separately published the results of PACCOCATH
ISR I ﬁrst-in-human trial (2006) (5), PACCOCATH ISR
I and II pooled 2-year outcomes (2008) (6), and
PACCOCATH ISR I and II pooled long-term analysis
(more than 5-year follow-up data [2012]) (12).
TRIAL CHARACTERISTICS. The main characteristics
of the individual studies are summarized in Table 1.
Regarding the type of ISR, 4 trials (7–9,19) exclu-
sively enrolled BMS ISR, and 5 trials (10,11,14,16,17)nalysis model. DEB ¼ drug-eluting balloon; DES ¼ drug-eluting stent;
TABLE 1 Characteristics of the Study
Trial (Year)
Treatment and No. of Patients
(N ¼ 1,862)
BMS or
DES ISR Inclusion Criteria Exclusion Criteria
Type of Device
Repeat
Revascularization
Indication MACE Deﬁnition
DAPT
Protocol CAG F/U Clinical F/U
DEB
(N ¼ 672)
DES
(N ¼ 694)
POBA
(N ¼ 496) DEB DES
ISAR-DESIRE
(2005)
N/A 200 100 BMS ISR Angina pectoris and/or
a positive stress
test þ BMS ISR
>50%
AMI, LM, DES-ISR N/A Cypher,
Taxus
Symptoms or
documented
ischemia with
stenosis >50% in
target vessel
N/R 6 months 6 months 1 yr
RIBS II (2008) N/A 76 74 BMS ISR Angina or documented
ischemia with BMS
ISR >50%
AMI, early (<4 wk) ISR,
before
brachytherapy
N/A Cypher Symptoms or
documented
ischemia with
stenosis >50% in
target vessel
Death (all) þ
MI þ TVR
9 months 9 months 4 yrs
PEPCAD II
(2009)
66 65 N/A BMS ISR Angina or documented
ischemia with BMS
ISR >70%
AMI, LM, ESRD, vessel
diameter <2.5 mm,
length >22 mm
Sequent
Please
Taxus,
Liberte
Symptoms or
documented
ischemia with
stenosis >70% in
target lesion
Death (all) þ
MI þ TLR
3 months
in DEB,
6 months
in DES
6 months 1 yr
Habara et al.
(2011)
25 N/A 25 DES ISR Angina or documented
ischemia with
sirolimus- eluting
stent ISR >50%
ACS, ESRD, ISR within
6 months, vessel
diameter <2.5 mm
or >3.5 mm, length
>26 mm
Sequent
Please
N/A Symptoms or
documented
ischemia with
stenosis >50% in
target lesion
Death (all) þ
MI þ TLR
6 months 6 months 6 months
ISAR-DESIRE 3
(2012)
137 131 134 DES ISR Angina or documented
ischemia with DES
ISR >50%
(everolimus-,
biolimus-,
zotarolimus-eluting
stent)
Acute STEMI, LM,
cardiogenic shock,
ESRD
Sequent
Please
Taxus
Liberte
Symptoms or
documented
ischemia with
stenosis >50% in
target lesion
Death (all) þ
MI þ TLR
6 months 6–8 months 1 yr
PEPCAD-DES
(2012)
72 38 N/A DES ISR Angina or documented
ischemia with DES
ISR >50%
(rapamycin-,
everolimus-,
sirolimus-,
paclitaxel-eluting
stent)
AMI, bifurcation, total
occlusion of
coronary artery, LM,
vessel diameter
<2.5 mm or
>3.5 mm, length
>22 mm
Sequent
Please
N/A Symptoms or
documented
ischemia with
stenosis >50% in
target lesion
Death (cardiac) þ
MI þ TLR
6 months 6 months 6 months
PACCOCATH-ISR
I&II Pooled
Analysis
(2012)
54 N/A 54 96% BMS
ISR, 4%
DES ISR
Angina or documented
ischemia with BMS
or DES ISR >70%
AMI, CRF (serum Cr
>2.0 mg/dl), vessel
diameter <2.5 mm,
length $30 mm
PACCOCATH N/A Symptoms or
documented
ischemia with
stenosis >70% in
target lesion
Death (all) þ MI þ
TLR þ stroke
1 month 6 months 5 yrs
CRISTAL (2012) N/A 136 61 DES ISR Angina or documented
ischemia with BMS
or DES ISR >50%
(sirolimus-,
paclitaxel-eluting
stent)
AMI, LM, thrombotic
occlusion,
bifurcation lesion,
CRF (serum Cr
>2.95 mg/dl),
vessel diameter
<2.25 mm or
>4 mm, length
>60 mm
N/A Cypher
Select
Symptoms or
documented
ischemia with
stenosis >50% in
target lesion
N/R 1 month for
POBA, 6
months
for DES
9 months 1 yr
Continued on the next page
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TABLE 1 Continued
Trial (Year)
Treatment and No. of Patients
(N ¼ 1,862)
BMS or
DES ISR Inclusion Criteria Exclusion Criteria
Type of Device
Repeat
Revascularization
Indication MACE Deﬁnition
DAPT
Protocol CAG F/U Clinical F/U
DEB
(N ¼ 672)
DES
(N ¼ 694)
POBA
(N ¼ 496) DEB DES
Habara et al.
(2013)
136 N/A 71 58% BMS
ISR,
42% DES
ISR
Angina or documented
ischemia with BMS
or DES ISR >50%
AMI, LVEF <30%, CRF
(serum Cr >1.5 mg/
dl), vessel diameter
<2.0 mm or
>4.0 mm, length
>22 mm
Sequent
Please
N/A Symptoms or
documented
ischemia with
stenosis >50% in
target lesion
Death (all) þ MI þ
TVR þ ST
3 months 6 months 6 months
PEPCAD China
ISR (2014)
109 106 N/A DES ISR Angina or documented
ischemia with DES
ISR >50%
AMI, bifurcation,
thrombus in target
vessel, CHF with
NYHA functional
class IV, ESRD,
vessel diameter
<2.5 mm or
>4.0 mm, length
>30 mm
Sequent
Please
Taxus
Liberte
Symptoms or
documented
ischemia with
stenosis >50% in
target lesion
TLF (CD þ
TVMI þ TLR)
12 months 9 months 1 yr
RIBS V (2014) 95 94 N/A BMS ISR Angina or documented
ischemia with BMS
ISR >50%
AMI, Early (<4 wk) ISR,
thrombus in target
vessel, vessel
diameter #2.0 mm,
length >30 mm
Sequent
Please
Xience
Prime
Symptoms or
documented
ischemia with stenosis
>50% in target vessel
Death (all) þ
MI þ TVR
3 months
for DEB,
1 yr
for DES
6–9 months 1 yr
Trial (Year) Age, yrs Male
Proportion of Comorbidities Pre-MLD, mm Pre-DS Lesion Length, mm Post-MLD, mm Post-DS
HTN DM Dyslipidemia Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 Group2
ISAR-DESIRE (2005) 64.3 78.3 54.3 27.7 56.7 DES
0.94
POBA
0.95
DES
62.4
POBA
61.8
DES
11.95
POBA
12.3
DES
2.54*
POBA
2.07
DES
9.35*
POBA
19.9
RIBS II (2008) 64.0 75.3 54.7 34.7 61.3 DES
0.74
POBA
0.70
DES
72.0
POBA
74.0
DES
16.9
POBA
15.7
DES
2.69*
POBA
2.29
DES
8*
POBA
40
PEPCAD II (2009) 64.8 74.8 81.7 29.8 74.8 DEB
0.74
DES
0.77
DEB
73.9
DES
72.8
DEB
15.7
DES
15.4
DEB
2.30
DES
2.56*
DEB
19.5
DES
11.2*
Habara et al. (2011) 69.4 86.0 64.0 62.0 62.0 DEB
0.99
POBA
0.92
DEB
64.1
POBA
68.4
DEB
12.7
POBA
13.2
DEB
1.99
POBA
2.00
DEB
25.7*
POBA
31.0
ISAR-DESIRE 3 (2012) 67.9 71.6 73.6 41.5 77.9 DEB
0.97
DES
0.93
POBA
0.88
DEB
64.4
DES
66.7
POBA
67.7
DEB
N/R
DES
N/R
POBA
N/R
DEB
2.29*
DES
2.53*
POBA
2.10
DEB
18.5*
DES
12.8*
POBA
23.3
PEPCAD-DES (2012) 67.8 70.9 94.5 35.4 78.2 DEB
0.66
POBA
0.62
DEB
72.1
POBA
74.0
DEB
11.2
POBA
12.2
DEB
2.15
POBA
2.14
DEB
12.6
POBA
13.7
PACCOCATH-ISR I&II
Pooled Analysis (2012)
65.9 67.6 81.5 26.9 75.0 DEB
0.70
POBA
0.63
DEB
N/R
POBA
N/R
DEB
18.6
POBA
18.3
DEB
2.34
POBA
2.43
DEB
N/R
POBA
N/R
CRISTAL (2012) 67.7 71.6 75.1 39.1 79.2 DES
1.09
POBA
1.18
DES
58.8
POBA
53.7
DES
14.6
POBA
13.4
DES
2.51*
POBA
2.12
DES
9.5*
POBA
18
Habara et al. (2013) 69.0 82.7 84.6 44.7 82.7 DEB
0.86
POBA
0.84
DEB
65.6
POBA
66.1
DEB
12.8
POBA
13.7
DEB
1.97
POBA
1.90
DEB
21.9
POBA
23.1
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387exclusively enrolled DES ISR. The remaining 2 trials
enrolled BMS or DES ISR; however, the majority
were BMS ISR (96% in the PACCOCATH ISR I and II
pooled analysis published in 2012; 58% in Habara
et al. [15] published in 2013) (12,15). Regarding the
complexity of lesion or clinical proﬁles, all trials
excluded the patients who had high-risk features of
PCI. Thus, all trials enrolled patients with stable or
unstable angina without high-risk features of PCI.
The DAPT protocols were different across the trials,
as presented in Table 1. Regarding treatment strate-
gies, trials with DEB as one of the treatment arms used
a paclitaxel-eluting balloon (Sequent Please, B. Braun
Melsungen AG, Berlin, Germany or PACCOCATH,
Bayer AG, Leverkusen, Germany), which were coated
with 3 mg/mm2 of paclitaxel on the balloon surface.
All trials (except the RIBS V trial) with DES as one
of the treatment arms used ﬁrst-generation DES
including sirolimus-eluting stents (Cypher or Cypher
Select, Cordis Corporation, Miami Lakes, Florida) or
paclitaxel-eluting stent (Taxus or Taxus Liberte,
Boston Scientiﬁc Corporation, Natick, Massachusetts).
Only the RIBS V trial used second-generation DES
(everolimus-eluting stent, Xience Prime, Abbott
Vascular, Illinois) to treat ISR of the previous stent
(Table 1) (13). As expected, the DES group mostly
showed a signiﬁcantly greater post-treatment mini-
mal lumen diameter or lower percentage of diameter
stenosis (%DS) than the DEB or POBA group. How-
ever, there were no signiﬁcant differences in post-
treatment minimal lumen diameter or %DS between
the DEB and POBA groups (Table 1).
RISK OF BIAS WITHIN TRIALS. Expanded descrip-
tions of the risk of bias assessment are presented in
the Online Appendix. A full description of the sum-
mary of risk of bias judgments of each study is
available in Online Figures 1 and 2 and Online Table 1.
COMPARISON OF OVERALL CLINICAL OUTCOMES OF
THE 3 TREATMENT STRATEGIES FOR ISR. As shown in
Figure 1, this meta-analysis included 11 RCTs (7–17),
all of which provided the incidence of TLR, MI, and
all-cause mortality. Figure 2 illustrates the Bayesian
ORs and 95% CrIs in a pooled comparison of DEB,
DES, and POBA to treat ISR. Both DEB (OR: 0.22, 95%
CrI: 0.10 to 0.42) and DES (OR: 0.24, 95% CrI: 0.11 to
0.47) signiﬁcantly reduced the risk of TLR at the
longest available follow-up in a random-effects
model compared with POBA as the reference group.
In a comparison of DEB and DES, the risk of TLR was
similar in the 2 groups (OR: 0.92, 95% CrI: 0.43 to
1.90). The odds of POBA werew4.1 to 4.5 times higher
than the odds of DEB or DES (Figure 2A). The signiﬁ-
cant beneﬁt of DEB or DES compared with POBA was
FIGURE 2 Results of Bayesian Network Meta-Analysis for Overall Rates of Clinical Outcomes in a Random Effects Model
Results of a Bayesian network meta-analysis with a random-effects model for the risk of target lesion revascularization (A), myocardial
infarction (B), all-cause mortality (C), major adverse cardiovascular events in longest available follow-up periods (D). CrI ¼ 95% credible
interval; MACE ¼ major adverse cardiac events; other abbreviations as in Figure 1.
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388consistently observed in both direct and indirect
estimates of the comparison with an acceptable
range of statistical heterogeneity (Online Figure 3A).
Regarding the risk of MI or all-cause mortality, there
was no difference in the 3 strategies. However, the
risk of MI was slightly higher after DES compared with
DEB and POBA, and all-cause mortality was slightly
higher after POBA compared with DEB or DES,
although these results were insigniﬁcant (Figures 2B
and 2C). The risk of MACE, mainly driven by TLR,
was signiﬁcantly lower in the DEB and DES groups
than in the POBA group, whereas it was similar in
the DEB and DES groups (Figure 2D). The pooled es-
timates on direct and indirect comparison were also
consistent without signiﬁcant heterogeneity in each
comparison for the risk of MI, all-cause mortality, and
MACE (Online Figures 3B to 3D). A ﬁxed-effects
model of a Bayesian network meta-analysis showed
results similar to those of a random-effects model
(Online Figure 4).
COMPARISON OF CLINICAL OUTCOMES IN 1-YEAR
OF THE 3 TREATMENT STRATEGIES FOR ISR. Be-
cause each trial had a different clinical follow-upperiod, all clinical events at 1-year follow-up were
also compared. As with the results of overall clinical
events, the risk of TLR or MACE at 1 year was signif-
icantly lower after DEB and DES than after POBA,
whereas it was similar between the DEB and DES
(Figures 3A and 3D). The risk of MI or all-cause mor-
tality showed a similar trend with overall clinical
events: insigniﬁcantly higher MI after DES than after
DEB and insigniﬁcantly higher mortality after POBA
than after DEB (Figures 3B and 3C).
COMPARISON OF ANGIOGRAPHIC OUTCOMES AT
6- TO 9-MONTH FOLLOW-UP ANGIOGRAPHY AND
THE INCIDENCE OF STENT THROMBOSIS. All trials
reported the incidence of binary restenosis, which
was evaluated at 6- to 9-month follow-up angiog-
raphy and quantitative coronary angiographic anal-
ysis. The risk of binary restenosis was signiﬁcantly
lower in the DEB (OR: 0.13, 95% CrI: 0.06 to 0.25)
and DES (OR: 0.20, 95% CrI: 0.09 to 0.40) groups
than in the POBA group, whereas it was not different
between the DEB and DES groups (OR: 0.66, 95%
CrI: 0.31 to 1.30) (Figure 4A). There was neither
inconsistency nor signiﬁcant heterogeneity across
FIGURE 3 Results of Bayesian Network Meta-Analysis for 1-Year Rates of Clinical Outcomes in Random-Effects Model
Results of a Bayesian network meta-analysis with a random-effects model for the risk of target lesion revascularization (A), myocardial
infarction (B), all-cause mortality (C), major adverse cardiovascular events within 1-year follow-up period (D). Abbreviations as Figures 1 and 2.
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389the direct or indirect comparison of risk of binary
restenosis (Figure 4C). Of the 11 RCTs, all trials
except ISAR-DESIRE (The Intracoronary Stenting or
Angioplasty for Restenosis Reduction – Drug-Eluting
Stents for In-Stent Restenosis) reported the incidence
of Academic Research Consortium–deﬁned stent
thrombosis. The risk of stent thrombosis (deﬁnite,
probable, or possible) was not different in the 3
treatment groups; however, a statistically signiﬁcant
inconsistency was observed (Figures 4B and 4D).
RANKING THE PROBABILITY OF EFFICACY AND
SAFETY OUTCOMES. Figure 5 shows the ranking
probability for each treatment option associated with
the lowest rate of each clinical outcome. For repeat
revascularization (efﬁcacy), there was a 59.9% prob-
ability that DEB were associated with the lowest rates
of TLR compared with DES (40.1%) and POBA (<0.1%)
(Figure 5A). As with the results of TLR, DEB consis-
tently showed the highest probability to be ranked
as the better treatment option for ISR in terms of
MI (63.0%), all-cause mortality (78.9%), and MACE
(74.1%) (Figures 5B to 5D). DES showed the highest
probability of being ranked as the second treatment
option for ISR in terms of TLR, all-cause mortality, orMACE, whereas in terms of MI, DES showed lowest
rank probability to reduce the risk of MI after treat-
ment for ISR (Figure 5B).
SENSITIVITY ANALYSES. For the risk of overall TLR,
sensitivity analyses were performed, as presented in
Figure 6. The results of the sensitivity analysis were
mostly similar to the results of the main analysis,
which showed signiﬁcantly reduced TLR with DEB or
DES than with POBA with no difference in the DEB
and DES groups. However, analysis of trials that
exclusively enrolled patients with BMS ISR or trials
with a DAPT duration <6 months showed a statisti-
cally nonsigniﬁcant trend favoring DEB or DES rather
than POBA. In addition, analysis after excluding trials
with unclear or non-blinded outcome assessment
showed similar results to the main analysis (Figure 6).
DISCUSSION
This is the ﬁrst Bayesian network meta-analysis that
compared the clinical efﬁcacy and safety of 3 different
current strategies (DEB, DES, and POBA) to treat ISR
of previously implanted BMS or DES. Our results
clearly show the superiority of DEB or DES to POBA in
FIGURE 4 Results of Bayesian Network Meta-Analysis for Binary Restenosis at 6- to 9- Month Follow-up Angiography and ARC-Deﬁned
Stent Thrombosis
Results of a Bayesian network meta-analysis with a random-effects model for the risk of binary restenosis (A), which was a measure by
quantitative coronary angiography, at 6- to 9-month follow-up angiography, and ARC-deﬁned stent thrombosis (deﬁnite, probable, or possible
stent thrombosis) (B). Analysis of consistency and heterogeneity in the network meta-analysis model for binary restenosis (C) and stent
thrombosis (D). ARC ¼ Academic Research Consortium; other abbreviations as in Figures 1 and 2.
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lesions or major adverse cardiovascular outcome. On
angiographic outcome analysis, DEB or DES also
showed a signiﬁcantly lower risk of binary restenosis
at 6- to 9-month follow-up angiography than POBA.
When we compared DEB and DES, the efﬁcacy was
comparable, whereas in terms of safety, DEB showed
a trend of lower risk of MI or all-cause mortality than
DES without statistical signiﬁcance. DEB had the
highest probability of being ranked as the ﬁrst treat-
ment option for ISR with the lowest risk of TLR, MI,
all-cause mortality, and MACE. The beneﬁcial effects
of DEB in reducing the risk of TLR were consistently
observed in various sensitivity analyses, regardless of
whether previous treatment was with BMS or DES.
DES had the highest probability of being ranked as the
second treatment option for ISR in terms of TLR, all-
cause mortality, and MACE. However, in terms of
MI, it showed lowest rank probability in reducing the
risk of MI after treatment for ISR.CURRENT STATUS OF STENT FAILURE: CLINICAL
IMPACT AND GUIDELINES. With the introduction of
contemporary second- or third-generation DES, the
rate of repeat revascularization due to ISR decreased,
but its prevalence is not negligible:w3% rate at 1-year
follow-up in Asian cohorts such as the EXCELLENT
(Efﬁcacy of Xience/promus versus Cypher in rEducing
Late Loss after stenting) randomized trial (20) or
RESOLUTE Korea registry (21). This failure rate would
be higher when PCI is performed in high-risk patients
with complex coronary lesions. Patients with com-
plex coronary lesions in Western cohorts showed an
w5% rate of binary restenosis at 13-month follow-up
angiography and an 8.6% rate of cumulative TLR at
4-year follow-up in the RESOLUTE All Comers trial
(22). The LEADERS (Limus Eluted From A Durable
Versus ERodable Stent Coating) trial also showed a
5.5% rate of binary restenosis and a 6.3% rate of TVR
at 5-year follow-up (23). Despite the progressive na-
ture of ISR, a substantial proportion of the patients
FIGURE 5 Probability Ranking of Each Treatment Arm Regarding Overall Clinical Outcomes
Graphs of the probability ranking of each treatment arm for the risk of target lesion revascularization (A), myocardial infarction (B), all-cause
mortality (C), major adverse cardiovascular events (D) in longest available follow-up periods. On the horizontal axis is the possible ranking of
each treatment (from best to worst according to the outcome). MI ¼ myocardial infarction; TLR ¼ target lesion revascularization; other
abbreviations as in Figures 1 and 2.
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391with ISR could present as acute coronary syndrome,
and the patients with ISR showed a signiﬁcantly
worse clinical outcome than the patients without ISR,
even after the successful treatment of ISR (1,24).
These results of previous studies imply that the
optimal treatment of patients with ISR is still an
important issue, even in the era of new-generation
DES. However, the current guidelines are limited to
DES (ACCF/AHA/SCAI 2011 guidelines for PCI; Class I,
Level of Evidence: A) or DEB (European Society of
Cardiology 2010 guidelines for myocardial revascu-
larization; Class IIa, Level of Evidence: B) for the
treatment of BMS ISR (3,4), with no consensus for the
treatment of DES ISR, which might be a more impor-
tant issue in real-world practice (3).
EFFICACY AND SAFETY OF DEB VERSUS DES FOR
ISR LESIONS. The current network meta-analysis
showed clear efﬁcacy of DEB or DES over POBA in
reducing the risk of TLR, regardless of the type of
previously placed stent (BMS or DES) (Figure 6).Although DEB was comparable to DES in reducing
TLR, it should be noted that DEB group showed a
signiﬁcantly smaller post-procedural minimal lumen
diameter (therefore less acute gain) and more severe
residual %DS than the DES group in the individual
trials (Table 1). Comparable efﬁcacy even with smaller
acute gain suggests that late loss after DEB would be
less than that of DES. Inserting an additional metal
structure in the ISR lesion would induce a substantial
degree of new tissue or thrombus deposition, which
would be less after using DEB. The most interesting
ﬁnding regarding the safety of the 3 different strate-
gies for ISR lesions was the disappointing results of
DES in MI risk. The probability to be ranked as the
ﬁrst treatment option in terms of MI was 63.0% with
DEB and only 1.7% with DES. This result implies the
potential hazard of implanting an additional polymer-
coated metal structure into the lumen of ISR, such as
delayed re-endothelialization and inﬂammation,
which are predisposing factors for stent thrombosis
FIGURE 6 Sensitivity Analysis for Overall Risk of Target Lesion Revascularization
Sensitivity analyses were performed by restricting the Bayesian network meta-analysis in a random-effects model to trials with bare metal stent
ISR, DES ISR, ﬁrst-generation DES as a treatment option for the ISR, DAPT duration of 6 months or longer, DAPT duration <6 months, or
blinded outcome assessment. DAPT ¼ dual-antiplatelet therapy; other abbreviations as in Figures 1 and 2.
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392and the late catch-up phenomenon (2,24). In addi-
tion, much less risk of side-branch occlusion with
DEB than DES in the treatment of ISR might be one of
the potential explanations for less development of MI
in the DEB group after treatment of ISR. However,
because none of included trials separately provided
the detailed incidence of periprocedural MI with the
incidence of MI originating from stent thrombosis,
this should be interpreted as hypothesis generating.
Previously, 2 meta-analyses evaluated the efﬁcacy
and safety of DEB, comparedwith POBA or DES (25,26).
On the basis of 4 or 5 RCTs, the 2 analyses reported
superior efﬁcacy of DEB compared with a control
group. However, they combined the 2 completely
different interventions (i.e., POBA andﬁrst-generation
DES) into 1 control group. Moreover, only 1 trial in each
meta-analysis compared the efﬁcacy of DEB with that
of DES. Therefore, the overall superior efﬁcacy of
DEB was mainly driven by the comparison with the
POBA group. Because DESs have constantly shown
superior efﬁcacy in the treatment of ISR compared
with POBA, one of the key questions in practice would
be the head-to-head comparison of DEB and DES. In
this context, mixing the results of DES with POBAcompromises the key comparison of importance
and cannot be justiﬁed. Our results are on the basis
of the highest number of RCTs and included the most
recent trials, which have not been used in previous
meta-analyses. In addition, using the Bayesian
approach also enables a true comparison of the 3
different modalities for ISR treatment.
Considering the results of the current network
meta-analysis, DEB might be the suitable ﬁrst-line
treatment for ISR of previously implanted BMS or
DES, especially in patients who cannot tolerate
long-term DAPT. Nonetheless, it should be noted
that 6 of 7 RCTs that had a DES arm to treat ISR
actually used old-fashioned ﬁrst-generation DES
such as sirolimus-eluting or paclitaxel-eluting stents.
Only the RIBS V trial used second-generation ever-
olimus-eluting stent (Xience Prime), which has been
proved to be superior to ﬁrst-generation DES (27). In
the RIBSV trial, DES were comparable to DEB both in
the rates of MI and TLR (13). However, due to the
limited sample size of the RIBS V trial, the comparison
of efﬁcacy and safety endpoints between DEB and
newer generation DES needs more evidence. Currently,
DARE (Drug Eluting bAlloon for In-stent Restenosis)
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393(NCT01127958) and RIBS IV (NCT01239940) trials are
ongoing comparing DEB with everolimus-eluting
stents to treat ISR. We hope future trials will clarify
the performance of DEB versus DES in the treatment of
ISR.
INFLUENCE OF DAPT DURATION ON THE PERFORMANCE
OF DEB OR DES FOR ISR LESIONS. On sensitivity
analysis according to the DAPT protocol, the superi-
ority of DEB or DES to POBA was inconclusive in a
pooled analysis of trials with a DAPT duration
<6 months, whereas it was more deﬁnite in the trials
with DAPT duration of longer than 6 months. This
result suggests that strategies of local drug delivery to
ISR lesions may delay the healing process and may
require a longer duration of DAPT. However, we can
point out that some trials with a DAPT duration of
<6 months had a different DAPT duration in each
treatment arm (7,12,13,15,17). In the CRISTAL (Cypher
Restenosis IntraSTent triAL) trial, in the POBA group,
a 1-month duration of DAPT was used compared with
6 months in the DES group, and in the RIBS V trial, a
3-month duration of DAPT was used in the DEB group
compared with 1 year in the DES group. Therefore,
the pooled analysis of trials with a DAPT duration <6
months could be biased among the treatment groups.
The optimal duration of DAPT to maximize the clin-
ical outcome after DEB angioplasty remains uncer-
tain. Further RCTs might be warranted regarding this
subject.
STUDY LIMITATIONS. Some important limitations of
the study should not be ignored. First, this meta-
analysis included clinically and methodologically
diverse studies, as mentioned earlier. Second, this
network meta-analysis has limited information
regarding the comparison between DEB and current
newer generation DES. Third, as this is a study-level
meta-analysis, we could not adjust for patient-level
confounders, especially the differences in post-
treatment minimal lumen diameter or %DS among
the treatment arms. Fourth, 2 of 11 RCTs onlyreported the incidence of TVR (Online Figure 5A)
(8,9), although we used TLR as a primary endpoint.
However, excluding those trials that presented only
the incidence of TVR, the overall results showed
exactly the same results as the original results
(Online Figure 5B). In addition, in the pooled analysis
regarding the incidence of TVR only, the overall
results were also similar to the original results
(Online Figure 5B). Fifth, some cautions are war-
ranted in interpreting the results of a pooled analysis
of stent thrombosis. There was a total of 16 events of
Academic Research Consortium–deﬁned deﬁnite or
probable stent thrombosis; 7 in the DES group, 4 in
the DEB group, and 5 in the POBA group. Among
them, 1 in the DEB and 4 in the POBA group were
probable or possible stent thrombosis, which was not
conﬁrmed by coronary angiography. The incidence of
events was extremely low with a wide CrI, and a
statistically signiﬁcant inconsistency was observed in
the pooled analysis of stent thrombosis. The duration
of DAPT differed among the 3 treatment groups in
each trial. Finally, all trials excluded the high-risk PCI
population, such as ISR presenting with acute MI or
ISR of an unprotected left main stent. Therefore, the
results of this network meta-analysis cannot be
applied to this high-risk PCI population.
CONCLUSIONS
Given the prognostic importance of ISR, the optimal
treatment strategy should be carefully selected. Our
results showed the efﬁcacy of DEB and DES to be
superior to that of POBA and similar efﬁcacy and
safety with DEB and DES.
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